PMID

Data

Article Title

Organization

Microbial hydroxylation and glycosylation of pentacyclic triterpenes as inhibitors on tissue factor procoagulant activity.

China Pharmaceutical University

Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors.

Bristol-Myers Squibb

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.

Bristol-Myers Squibb R & D

Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.

Bristol-Myers Squibb Research & Development

Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.

Bristol-Myers Squibb R & D

Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.

Bristol-Myers Squibb Research & Development

Applications of Fluorine in Medicinal Chemistry.

Bristol-Myers Squibb Research And Development

Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.

TBA

Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors.

Bristol-Myers Squibb R & D

Chemical and microbial semi-synthesis of tetrahydroprotoberberines as inhibitors on tissue factor procoagulant activity.

China Pharmaceutical University

Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.

University Of Minnesota

The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex--Part 2.

Pfizer

Phage-encoded combinatorial chemical libraries based on bicyclic peptides.

Laboratory Of Molecular Biology, Medical Research Council

Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidate.

F. Hoffmann-La Roche

Design, synthesis, and biological evaluation of 1,5-benzothiazepine-4-one derivatives targeting factor VIIa/tissue factor.

University Of Montpellier

Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.

Searle Discovery Research

Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands.

Astellas Pharma

Potent 4-amino-5-azaindole factor VIIa inhibitors.

Celera Genomics

Factor VIIa inhibitors: improved pharmacokinetic parameters.

Celera Genomics

Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.

Celera Genomics

The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex.

Pfizer

Optimization of a screening lead for factor VIIa/TF.

Axys Pharmaceuticals